×
About 21,004 results

ALLMedicine™ Detailed topics Center - Guidelines

ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection
https://www.medrxiv.org/content/10.1101/2020.02.12.20022418v1

In December 2019 and January 2020, novel coronavirus (2019-nCoV) - infected pneumonia (NCIP) occurred in Wuhan, and has already posed a serious threat to public health. ACE2 (Angiotensin Converting Enzyme 2) has been shown to be one of the major receptors that mediate the entry of 2019-nCoV into human cells, which also happens in severe acute respiratory syndrome coronavirus (SARS). Several res...

Covid-19 pandemic and the skin - What should dermatologists know?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102542/
Clinics in Dermatology;

The World has changed dramatically since the COVID-19 pandemic began. Together with our social, occupational, and personal life, the new corona virus poses novel challenges for all physicians, including dermatologists. Despite the virus not being dermatotropic, several skin conditions have emerged, mainly as a result of prolonged contact to personal protective equipment and excessive personal h...

Cardiovascular disease and COVID-19
https://www.sciencedirect.com/science/article/pii/S1871402120300539
Diabetes & Metabolic Syndrome: Clinical Research & Reviews;

Many patients with coronavirus disease 2019 (COVID-19) have underlying cardiovascular (CV) disease or develop acute cardiac injury during the course of the illness. Adequate understanding of the interplay between COVID-19 and CV disease is required for optimum management of these patients.

Muscle-invasive and Metastatic Bladder Cancer
https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/

The European Association of Urology (EAU) Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) have prepared these guidelines to help urologists assess the evidence-based management of MIBC and to incorporate guideline recommendations into their clinical practice.

Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals
https://www.tandfonline.com/doi/full/10.1080/09273948.2020.1738501
Ocular Immunology and Inflammation;

In December 2019, a novel coronavirus (CoV) epidemic, caused by the severe acute respiratory syndrome coronavirus – 2 (SARS-CoV-2) emerged from China. This virus causes the coronavirus disease 2019 (COVID-19). Since then, there have been anecdotal reports of ocular infection. The ocular implications of human CoV infections have not been widely studied. However, CoVs have been known to cause var...

Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients
https://www.biorxiv.org/content/10.1101/2020.03.25.009084v2.full

Recent reports suggest an association between COVID-19 and altered olfactory function. Here we analyze bulk and single cell RNA-Seq datasets to identify cell types in the olfactory epithelium that express molecules that mediate infection by SARS-CoV-2 (CoV-2), the causal agent in COVID-19. We find in both mouse and human datasets that olfactory sensory neurons do not express two key genes invol...

Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously
https://www.ijidonline.com/article/S1201-9712(20)30235-6/pdf
International Journal of Infectious Diseases;

Since the outbreak of coronavirus disease (COVID-19) in Wuhan in December 2019, by March 10, 2020, a total of 80,932 confirmed cases have been reported in China. Two consecutively negative RTPCR test results in respiratory tract specimens is required for the evaluation of discharge from hospital, and oropharyngeal swabs were the most common sample. However, false negative results occurred in ...

The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer
https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ20-0025/_pdf/-char/en
Endocrine Journal;

 The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the therapeutic management of thyroid cancers. The objective of the guidelines is to improve health-related outcomes in patients with thyroid tumors by en...

Cancer Pain (PDQ®)–Health Professional Version
https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq?cid=eb_govdel

Pain is one of the most common symptoms in cancer patients and often has a negative impact on patients’ functional status and quality of life. The goal of the following summary is to provide evidence-based, up-to-date, and practical information on the management of cancer pain.

Bladder Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq?cid=eb_govdel

Bladder cancer is the sixth most common cancer in the United States after lung cancer, prostate cancer, breast cancer, colon cancer, and lymphoma. It is the third most common cancer in men and the eleventh most common cancer in women. Of the roughly 70,000 new cases annually, about 53,000 are in men and about 18,000 are in women. Of the roughly 15,000 annual deaths, more than 10,000 are in men ...

Serology Testing for COVID-19 at CDC
https://www.cdc.gov/coronavirus/2019-ncov/lab/serology-testing.html

CDC has developed a laboratory blood test to assist with efforts to determine how much of the U.S. population has been infected with SARS-CoV-2, the virus that causes COVID-19. CDC is also using its serologic test (antibody) to evaluate the performance of commercial antibody tests.

The new International Society of Hypertension guidelines on hypertension
https://journals.lww.com/jhypertension/Fulltext/2020/06000/The_new_International_Society_of_Hypertension.1.aspx?context=LatestArticles
Journal of Hypertension;

The June issue of the Journal of Hypertension starts with the hypertension guidelines prepared by the International Society of Hypertension (ISH) and simultaneously published in Hypertension as well. Compared with the guidelines issued by the European Society of Cardiology (ESC)/European Society of Hypertension (ESH) and American College of Cardiology (ACC)/American Heart Association (AHA) the ...

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 29th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (amantadine) extended release capsules on these episodes.

Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
https://link.springer.com/article/10.1007/s00702-018-1900-6
Neurology and Preclinical Neurological Studies;

Jul 2nd, 2018 - Symptoms of Parkinson’s disease have been controlled with levodopa for many years; however, motor complications consisting of wearing off of medication effect and dyskinesias tend to occur within a few years of starting levodopa. Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to be 6.5 years. Dyskinesias can be troublesome and require ...

Hypertension and the Risk of Dementia
https://www.frontiersin.org/articles/10.3389/fcvm.2020.00005/full

Hypertension, particularly midlife high blood pressure, has been related to a higher risk of cognitive decline and dementia, including Alzheimer disease. However, these associations are complex and not fully elucidated. Cerebral small vessel disease emerges as one of the most important causes. Several observational studies have shown the potential beneficial role of antihypertensive treatment i...

Impairments in Activities of Daily Living in Parkinson's Disease: Implications for Management
https://pubmed.ncbi.nlm.nih.gov/14530586/
NeuroRehabilitation

Sep 9th, 2003 - Parkinson's disease (PD) is a neurodegenerative disorder with progressive impairment in motor and cognitive functioning. A review of past research shows that individuals experience not only physical discomfort brought on by the illness, but also considerable psychological distress. Increased dependency on a caregiver due to impairments in activities of daily living (e.g., walking, eating, dress...

Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications
https://www.frontiersin.org/articles/10.3389/fneur.2014.00242/full
Frontiers in Neurology;

Dec 14th, 2014 - The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson’s disease (PD) for over 40 years. However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.

Investigation of antihypertensive class, dementia, and cognitive decline
https://n.neurology.org/content/94/3/e267.abstract

High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimizing cognition. Our objective was to determine whether any particular antihypertensive class was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original p...

Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 16th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.